| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Transaction costs paid pursuant to private placement | 0 | 0 |
| Net cash provided by financing activities | 13,900 | -469 |
| (decrease) increase in cash, cash equivalents and restricted cash | -107,433 | -92,176 |
| Cash and cash equivalents at beginning of period | 134,696 | - |
| Cash and cash equivalents at end of period | 27,263 | - |
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)